with low-grade NHL, the role of high-dose therapy with autologous stem cell support is less well defined. 2-4 Several reports of high-dose therapy and autologous stem cell supForty-nine patients with low-grade non-Hodgkin's lymphoma (NHL) received high-dose chemotherapy (HDC) port for patients with NHL have included patients with lowgrade histology. [5] [6] [7] [8] [9] [10][11] In addition, several recent studies have with busulfan and cyclophosphamide (BUCY) or carmustine, etoposide, cytarabine and CY (BEAC) followed specifically evaluated the outcome of patients with lowgrade NHL who have received high-dose therapies with stem by unpurged autologous peripheral blood stem (PBSC) infusion. All patients had failed initial chemotherapy or cell support after failure of conventional therapy. 3, 4, [12] [13] [14][15] [16] [17] [18] [19] [20] [21][22][23][24] [25] [26] One study has evaluated cyclophosphamide (CY) and TBI with progressed after an initial remission. Peripheral blood stem cells were mobilized with CY alone (n = 1), CY, stem cell support in patients with follicular lymphoma treated during first remission. 
Patients were classified according to the Working ForCarmustine, etoposide, cytarabine, cyclophosphamide (BEAC): Twenty-seven patients received carmustine mulation. 28 Primary induction failure was defined as failure to achieve a CR following initial remission induction. Com-300 mg/m 2 on day −7, etoposide 150 mg/m 2 twice a day on days −6, −5, −4 and −3 (1200 mg/m 2 ), cytarabine plete remission was defined as total resolution of measurable radiographic or clinical disease. Partial remission (PR) 100 mg/m 2 twice a day on days −6, −5, −4 and −3 (800 mg/m 2 ), and CY 35 mg/kg/day on days −6, −5, −4 and was defined as greater than 50% reduction in the product of the perpendicular diameter of measurable disease. Sensitive −3 (140 mg/kg). 33 All drugs were administered intravenously over 30-60 min. disease was defined as уPR to reinduction chemotherapy. Patients who were induction failures or in untreated first Thirty-nine of 49 patients (80%) received G-CSF 6 g/kg/day s.c. or granulocyte-macrophage colony-stimurelapse were not categorized for chemotherapy sensitivity.
Prior radiotherapy was defined as radiotherapy adminislating factor (Immunex, Seattle, WA, USA) 250 g/m 2 /day starting on day 1-3 until the ANC count was у0.5 × 10 9 /l tered to any site at any dose before the administration of mobilization chemotherapy. Mediastinal irradiation was for 3 consecutive days and 10 received no growth factor after infusion of PBSC. defined as у2000 cGy.
Treatment centers Definitions of engraftment and toxicity grading
Patients were treated in one of 19 participating community Neutrophil engraftment was defined as the first of 3 conmedical centers in the United States under the care of 37 secutive days on which the absolute neutrophil count community oncologists affiliated with the Clinical Trials (ANC) was у0.5 × 10 9 /l following the nadir. Platelet Division of Response Oncology, Inc. (ROI), Memphis, TN, engraftment was defined as the first of 7 consecutive days listed at the end of this manuscript. 29 Chemotherapy was on which the platelet count exceeded 20.0 × 10 9 /l unsupadministered and PBSC harvested in an outpatient facility ported by transfusions. by nurses and medical technicians. Initially, at the comAll patients were evaluated daily until resolution of signs pletion of PBSC infusions, patients were admitted to hospiand symptoms and graded for toxicity using standard critals meeting the criteria of ASCO/ASH guidelines for stem teria. 34 Interstitial pneumonia syndrome (IPS) was defined cell transplantation. 30 As experience was acquired, patients as diffuse pulmonary infiltrates without identifiable infecremained in the Outpatient Department and were admitted tious cause. 35 Veno-occlusive disease of the liver (VOD) only for complications such as fever and poor oral intake.
was defined as liver toxicity secondary to chemotherapy, and the diagnosis was made on the basis of hepatomegaly and/or liver tenderness, weight gain Ͼ2% of baseline and Mobilization of PBSC an elevated serum bilirubin Ͼ2 mg/dl and/or histologically Patients had PBSC collected following the administration by damage to the endothelial cells at the termini of hepatic of CY alone (n = 1), CY, etoposide (CE) (n = 19) or CY, venules, dilatation of the sinusoids and necrosis of etoposide, cisplatin (CEP) (n = 29) and granulocyte colonyhepatocytes.
36
stimulating factor (G-CSF; Amgen, Thousand Oaks, CA, USA) as previously described. 29, 31 Patients receiving Statistical analysis BUCY had PBSC mobilized by CE (n = 2) or CEP (n = 20) and patients receiving BEAC had PBSC mobilized with CY Treatment, laboratory and toxicity data were collected by alone (n = 1), CE (n = 17) or CEP (n = 9). The goal was to research nurses locally and entered into a custom designed collect у2.5 × 10 6 CD34 + cells/kg and five patients who distributed data system. All data were internally audited at achieved less than this target dose underwent a second a central clinical trials center (ROI) by clinical trials invesmobilization procedure. 29, 31 tigators and analyzed using the SAS system (SAS Institute, Cary, NC, USA). Disease characteristics and response assessments were reviewed centrally by a single investiCollection and cryopreservation of PBSC gator (CH Weaver) for consistency. Peripheral blood stem cells were collected and cryopreProportions were compared using 2 or Fisher's exact served as previously described. 29, 31 Cryopreserved PBSC test as appropriate and quantitative variables were comwere thawed and infused 48-72 h after the last dose of pared using the Wilcoxon rank sum test. Days to neutrophil chemotherapy. The day of PBSC infusion was designated and platelet recovery, probabilities of relapse/progression, day 0. No attempts were made to purge grafts of maligsurvival and EFS were estimated using the product-limit nant cells. method according to Kaplan and Meier and were compared using the log rank test. 37 The Cox regression model was used to perform multivariate analyses on survival outcome High-dose chemotherapy variables. Survival was measured from day 0 (day of PBSC infusion) to death, censored for the date of last contact. The Busulfan, cyclophosphamide (BUCY): Twenty-two patients received BU 4 mg/kg/day orally for 4 consecutive endpoint for progression/relapse was the first clinical or pathological evidence of progression of disease, or of days for a total dose of 16 mg/kg followed by CY 60 mg/kg i.v. on each of 2 successive days for a total dose of relapse if patients were in CR. The endpoint for EFS was progression/relapse or death without progression/relapse 120 mg/kg. 32 censored for the date of last contact. The date of last followsecond harvests were added to first harvests, the median number of CD34 + cells collected was 7.99 × 10 6 kg (range, up was 10 July 1997.
1.88-74.9) and only one patient failed to achieve у 2.5 × 10 6 CD34 + cells/kg. Results
High-dose chemotherapy Patient characteristics
Hospitalization: All 49 patients were hospitalized a median Characteristics of patients receiving BUCY or BEAC are of 14 days (range, 7-75). The median number of hospital listed in Table 1 . Patients in the BEAC group were older days for patients receiving BUCY was 14 (range, 7-34) (P = 0.031) and had a higher proportion of females compared to 14 (range, 10-75) for patients receiving (P = 0.025) than patients in the BUCY group.
BEAC (P = 0.94). /l in the remaining 47 patients was 10 (range, [8] [9] [10] [11] [12] [13] [14] . Two patients died on days 10 and 75 with a median of three (range, 2-10) aphereses. Five patients failing to achieve у 2.5 CD34
Administration of mobilizing chemotherapy and collection
+ cells × 10 6 /kg before platelet recovery. The median day for platelet recovery for the 47 remaining patients was 11 (range, 4-52). The underwent a second mobilization procedure where a median of 1.71 × 10 6 CD34 + cells/kg (range, 0.06-10.88) was colmedian day to achieving an ANC у0.5 × 10 9 /l for patients receiving BUCY was 10 (range, 8-14) compared to 10 lected in a median of four (range, 2-5) aphereses. When Twenty-two patients with low-grade NHL who had failed conventional treatment received HDC with a BUCY regi-(range, 4-38) for patients receiving BEAC (P = 0.25).
men followed by the infusion of unpurged PBSC. The probability of relapse for patients receiving BUCY was 0.57 Transplant-related mortality: Four patients (8%) died of non-relapse causes, one from IPS on day 75, two from with an overall survival of 0.58 and an EFS of 0.36. These outcomes were not different than for 28 patients receiving VOD on days 39 and 61 and one from pulmonary edema on day 10. Two patients who died received BUCY (9%) BEAC. However, this was not a randomized study and patients receiving BEAC were older and had PBSC mobiland two received BEAC (7%).
ized with a less intensive regimen (CE) than patients receiving BUCY, where most received CEP. Because of the Relapse/progression (Figure 1) : Twenty-seven patients (54%) relapsed or progressed at a median of 9.4 months uncontrolled nature of the study and the small numbers of patients evaluated, differences between regimens can only (range, 2-38) from PBSC infusion. Ten patients are alive a median of 31 months (range, 6-47) months after relapse.
be determined by performing a prospective randomized controlled trial. In a current study, however, it is unlikely The probabilities of relapse at 3.6 years for patients receiving BUCY or BEAC were 0.57 and 0.70, respectively that the administration of CY at a dose of 120 mg/kg accounts for the observed EFS of 36%. Thus, the main (P = 0.92).
importance of the current study is the demonstration that BU is an active agent for the treatment of patients with Survival (Figure 2 ): Twenty-seven patients (55%) are alive at a median of 3.6 years (range, 1-5). The probabilities of low-grade NHL and is a drug that could be incorporated into new HDC regimens. survival at 3.6 years for patients receiving BUCY or BEAC were 0.58 and 0.55, respectively (P = 0.72).
Regimens involving BU were developed primarily as an alternative to TBI in patients with myeloid malignancies. 33 ,38,39 Studies of BU-based regimens in patients Event-free survival (Figure 3 ): Seventeen patients (35%) are alive without relapse at a median of 3.1 years (range, with lymphoid malignancies are few and there have been no previous reports of BUCY and autologous stem cell sup-1-5). The probabilities of EFS at 3.6 years for patients receiving BUCY or BEAC were 0.36 and 0.28, respectport for the treatment of patients with NHL. However, there have been reports evaluating BUCY followed by allogeneic ively (P = 0.82).
marrow transplantation for the treatment of patients with lymphoid malignancies demonstrating significant Multivariate analyses: There were no statistically significant differences in survival, EFS or relapse between activity. [40] [41] [42] More recently a regimen of BU, melphalan and thiotepa followed by autologous PBSC support has patients receiving BUCY or BEAC when age, gender, ECOG performance status, chemotherapy response, number shown significant activity in patients with NHL but has not been specifically evaluated in patients with low-grade lymof chemotherapy regimens, radiation therapy, bone marrow involvement, mobilization regimen (CE vs CEP) and interphoma.
43-45
Other investigators have evaluated BEAC in patients val from diagnosis to HDC were entered into multivariate analyses.
with low-grade NHL. 12, 25 However, because of the differ- ences in patient selection, comparison of published outreceiving autologous transplants have been treated with regimens containing TBI. Cyclophosphamide with or withcomes with the outcome of the 27 patients treated with BEAC in this study is probably not meaningful. A similar out etoposide has been combined with TBI and comprises the most frequently reported regimens for the treatment of regimen substituting melphalan for cyclophosphamide (BEAM) has been more extensively evaluated than BEAC patients with low-grade lymphoma.
10,12,14, [16] [17] [18] 20, 21, [23] [24] [25] 27 There have been no formal comparisons between patients in patients with low-grade NHL. 15, 16, 22, 24 Since CY is invariably used in the mobilizing regimen, BEAM may be with low-grade lymphoma receiving TBI or HDC regimens. One institution has reported no difference in outcomes a better drug combination than BEAC. In addition, the administration of high-dose melphalan obviates the need between patients with low-grade lymphoma receiving BEAC or a TBI-based regimen. 25 However, the validity of for administering mesna to prevent hemorrhagic cystitis from CY. The combination of mitoxantrone and melphalan such retrospective comparisons is suspect since many centers administer HDC regimens to patients who have had is also effective in patients with low-grade lymphoma. 26 The majority of patients with low-grade lymphoma dose-limiting radiation therapy and TBI-based regimens to 
